Biotechnology in the Heart of the Capital City
CSL Behring is a global leader in developing and delivering high-quality medicines that treat people with rare and serious diseases. Our treatments offer promise for people in more than 100 countries.
CSL Behring News
Half Year Results 2023/2024
CSL reported net income after tax of $2.02 billion in the first half of 2024.
Diplomatic visit to CSL Behring in Bern
As part of a visit to the cantonal government, a visit to CSL Behring in Bern was also on the agenda.
Swissmedic Approval for HEMGENIX®
Swissmedic Authorises CSL’s HEMGENIX® as First Gene Therapy for Hemophilia B
Youngsters eyes light up at the Wankdorf Stadium
Children of CSL Behring employees as run-in kids at BSC Young Boys!
CSL further expands its R&D network in Switzerland
New office space on the premises of Switzerland Innovation Park Basel Area